Implantable device cuts obstructive sleep apnea symptoms

June 10, 2016, University of Pennsylvania School of Medicine

Since the 1980s, continuous positive airway pressure (CPAP) - in which positive pressure is pushed through the nasal airways to help users breathe while sleeping - has been by far the most widely used treatment for obstructive sleep apnea (OSA). With more than 18 million people experiencing OSA, a number expected to rise, new results from a Penn case study of a new device implanted in the chest called hypoglossal nerve stimulation (HGNS) offers promise for patients with moderate to severe OSA who cannot tolerate CPAP. Researchers at the Perelman School of Medicine at the University of Pennsylvania will present data (abstract 0378) on their outcomes with hypoglossal nerve stimulation for the treatment of patients with sleep apnea at SLEEP 2016, the 30th annual meeting of the Associated Professional Sleep Societies LLC.

The is a pacemaker with a tiny generator and a sensing lead, but instead of using electrical pulses to control abnormal heart rate, the device uses two wires to stimulate the tongue. Patients use a remote control to turn on the device before going to sleep and turn it off upon waking up. A delay allows the user to fall asleep before the pulse generator begins stimulation. After detecting the user's breathing pattern, the machine stimulates the hypoglossal nerve (the nerve that controls tongue motion) which enlarges the upper airway.

In the current Penn case study, 20 implants were completed at the University of Pennsylvania between January 2015 and March 2016. All had information from a baseline polysomnography (PSG) recording prior to HGNS implant, as well as a post PSG approximately two months after HGNS, to assess the severity of their apnea and any change after treatment. Those who received the implant were typically overweight, middle aged, and had severe OSA.

Total apnea-hypopnea index (AHI) - which measures severity of sleep apnea by counting the number of pauses in breathing during sleep - for all patients significantly decreased an average of 35 events per hour after the device was planted, which corresponds to an average reduction of 84 percent. Additionally, the lowest oxygen level measured in the blood during the night significantly increased by 11 percent, from 79 percent to 90 percent.

In the previous STAR clinical trial, NCT01161420, which led to the device's FDA approval in April 2014 for patients unable to tolerate CPAP, patients implanted with the Inspire Upper Airway Stimulation device showed a 78 percent reduction in AHI and 80 percent fewer oxygen desaturation events (number of times the oxygen levels in the blood were low). These results were sustained three years after the device was implanted.

The STAR trial was conducted under controlled conditions, while the Penn study takes the next step by looking at outcomes in post-approval clinical use of the device. By replicating the success of the clinical trial, the findings show that the device is as successful in the general clinical population as it was in participants that met the previous clinical trial criteria.

"Considering that sleep apnea can lead to high blood pressure, heart attack, stroke, and other serious health problems, it is critically important that we study devices that may serve as another option instead of CPAP to treat patients with sleep apnea," said lead author Richard Schwab, MD, co-medical director of the Penn Sleep Center. "There is no perfect treatment option for , but our preliminary data suggest that hypoglossal can effectively treat patients with who are unable to tolerate CPAP."

Explore further: New implantable device eases sleep apnea

Related Stories

New implantable device eases sleep apnea

June 6, 2016
Mike Freeman's backpacking buddies did not want their tents near his, and his wife was tired of waking in the middle of the night to get him to roll over and stop snoring. Mike has sleep apnea, a pretty dramatic case, he ...

Clinical trial underway for treatment of sleep apnea in adolescents with Down syndrome

May 9, 2016
An FDA-approved clinical trial is underway at Massachusetts Eye and Ear and Massachusetts General Hospital for Children to evaluate the use of a hypoglossal nerve stimulator—a technology currently available to adults with ...

Cranial nerve stimulation shows promise as sleep apnea tx

October 1, 2015
(HealthDay)—An implanted cranial nerve stimulation device might improve sleep patterns and quality of life for patients with obstructive sleep apnea (OSA), according to findings presented this week at the annual meeting ...

Sleep apnea treatment may reverse unhealthy brain changes

September 15, 2015
(HealthDay)—Sleep apnea treatment may reverse changes in brain stem activity associated with increased risk of heart disease, a new study suggests.

Still tired after getting your zzz's? You might have sleep apnea

March 14, 2016
(HealthDay)—Many Americans will be feeling sleepy in the days after Daylight Saving Time starts. But some people with sleep apnea wake up feeling exhausted every morning.

Recommended for you

Synthetic cannabinoid reduces sleep apnea

November 29, 2017
A synthetic version of a molecule found in the cannabis plant was safe and effective in treating obstructive sleep apnea in the first large, multi-site study of a drug for the sleep disorder funded by the National Institutes ...

Sleeping through the snoring: Researchers identify neurons that rouse the brain to breathe

November 2, 2017
A common and potentially serious sleep disorder, obstructive sleep apnea affects at least one quarter of U.S. adults and is linked to increased risk of diabetes, obesity and cardiovascular disease. In a paper published today ...

Remede system approved for sleep apnea

October 9, 2017
(HealthDay)—The Remede sleep system, an implanted device that treats central sleep apnea by activating a nerve that sends signals to the diaphragm to stimulate breathing, has been approved by the U.S. Food and Drug Administration.

Inflammation may precede sleep apnea, could be treatment target

September 1, 2017
Inflammation is traditionally thought of as a symptom of sleep apnea, but it might actually precede the disorder, potentially opening the door for new ways to treat and predict sleep apnea, according to researchers.

More evidence: Untreated sleep apnea shown to raise metabolic and cardiovascular stress

August 31, 2017
Sleep apnea, left untreated for even a few days, can increase blood sugar and fat levels, stress hormones and blood pressure, according to a new study of sleeping subjects. A report of the study's findings, published in the ...

Sleep patterns contribute to racial differences in disease risk

August 18, 2017
Poor sleep patterns could explain, in part, the differences in the risk of cardiometabolic disease between African-Americans and European-Americans, according to a new study published in Proceedings of the National Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.